louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01323413: Determinants of Penumbra in Acute Ischemic Stroke Patients
Official title: Determinants of Penumbra in Acute Ischemic Stroke Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Ischemic Stroke
Keywords: stroke
penumbra
determinants
CT perfusion
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2011-03-25
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: neurological ward

Brief summary: The purpose of the study is to examine the influence of demographic, clinical and laboratory characteristics on the presence and size of penumbra in acute ischemic stroke patients and to determine those of them which related significantly and independently to the presence and size of Penumbra. The examined factors will include demographic variables such as age, gender, ethnic background, vascular risk factors and medical history, clinical parameters such as time from stroke onset until arrival to the hospital, results of neurological evaluation by NIHSS and imaging findings, laboratory tests such as body temperature, blood pressure, glucose level, renal functions etc. and imaging findings - the presence and the size of collateral blood vessels, the state of carotid arteries (by CTA). The possible correlation between all this parameters and the presence and the size of penumbra as detected by CTP will be further examined.


Eligibility criteria: Inclusion Criteria:

* Acute ischemic stroke patients hospitalized in Rambam Health Care Campus between 2008-2010, and which have underwent neurological evaluation including NIHSS scale, Brain CT, CT angio and Ct perfusion.

Exclusion Criteria:

* Intracranial hemorrhage of any other brain condition

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
References:
Clinical trial NCT07008313: Enhanced Recovery After Surgery Promotes the Rehabilitation of Patients With Acute Gastrointestinal Perforation in Perioperative Period
Official title: Enhanced Recovery After Surgery Promotes the Rehabilitation of Patients With Acute Gastrointestinal Perforation, a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Gastrointestinal Perforation
Enhanced Recovery After Surgery
Keywords: acute gastrointestinal perforation
enhanced recovery after surgery
perioperative period
Lead sponsor: Hebei Medical University
Sponsor class: OTHER
First posted: 2025-06-06
Enrollment: 362
Sex: ALL
Minimum age (years): 14
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The enhanced recovery after surgery(ERAS) has been gradually extended from its initial colorectal surgery to almost all surgical fields. However, there are few reports about the application value of ERAS in emergency surgery. The goal of this clinical trial is to evaluate the value of ERAS in the perioperative period of acute gastrointestinal perforation. All the patients will be treated by emergency operation. The changes of CRP, PA, PCT in Plasma 1 hour before operation and 1,3,7 days after operation, the operation time, the amount of bleeding during operation, the recovery time of intestinal function and the time of the first meal after operation,the incidence of postoperative complications, the degree of postoperative pain, the time of first out-of-bed activity, fatigue and mental status, quality of life, the length and the cost of hospital stay will be monitored and recorded.


Eligibility criteria: Inclusion Criteria:

* Age≥14years old and ≤80 years old
* The initial diagnosis is acute gastrointestinal perforation

Exclusion Criteria:

* Patients with unconsciousness,or patients with past psychiatric history
* Patients with shock and/or severe organ failure
* Patients who are pregnant
* Patients with severe spinal deformity who are unable to receive epidural anesthesia

Primary outcomes:
measure: change of the c-reactive protein in plasma
timeFrame: 1, 3, and 7 days after surgery
measure: change of the prealbumin in plasma
timeFrame: 1, 3, and 7 days after surgery
measure: change of the procalcitonin in plasma
timeFrame: 1, 3, and 7 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Shijiazhuang
country: China
facility: the Second Hospital of Hebei Medical University
state: Hebei
Study officials:
References:
Clinical trial NCT02216513: Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Official title: Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: EARLY_PHASE1
Conditions: Subarachnoid Hemorrhage
Keywords: subarachnoid hemorrhage
SAH
DFO
cerebral autoregulation
delayed cerebral ischemia
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: Dr. Jeffrey Thomas Stroke Shield Foundation
First posted: 2014-08-15
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.


Eligibility criteria: Inclusion Criteria:

* diagnosis of spontaneous SAH
* impaired cerebral autoregulation on day 2-4 post SAH

Exclusion Criteria:

* traumatic SAH
* other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations
* pregnancy
* severe renal disease or anuria

Primary outcomes:
measure: delayed cerebral ischemia (DCI)
timeFrame: 6 weeks post hemorrhage
Secondary outcomes:
measure: Clinical outcome at discharge
timeFrame: patient's discharge date, which averages 3-4 weeks post hemorrhage
Other outcomes:
measure: Cerebrovascular function (i.e., cerebral autoregulation)
timeFrame: 5 days after initiation of study drug
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Farzaneh A Sorond, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Van der Loo LE, Aquarius R, Teernstra O, Klijn K, Menovsky T, van Dijk JMC, Bartels R, Boogaarts HD. Iron chelators for acute stroke. Cochrane Database Syst Rev. 2020 Nov 24;11(11):CD009280. doi: 10.1002/14651858.CD009280.pub3.
Clinical trial NCT06520813: Analysis and Measurement of Nail Morphology
Official title: Analysis and Measurement of Nail Morphology
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Morphology
Keywords: Nail
Measure
Curvature
Morphology
Lead sponsor: University of Seville
Sponsor class: OTHER
First posted: 2024-07-25
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population that attends the pathology service, without randomization

Brief summary: It consists of measuring the nail plate in its different areas.

Detailed description: It consists of measuring the nail plate in its different areas. This will not modify or alter the nail plate

Eligibility criteria: Inclusion Criteria:

* Healthy patients
* Patients without any treatment on the nail plate

Exclusion Criteria:

* Pregnant patients
* Patients with uncontrolled systemic diseases

Primary outcomes:
measure: Normal length in milimeters of the nail plate
timeFrame: 1 year follow-up
measure: Normal width in milimeters of the nail plate
timeFrame: 1 year follow-up
measure: Normal curvature in degrees of the nail plate
timeFrame: 1 year follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Sevilla
country: Spain
facility: Clinica Rayo
Study officials:
affiliation: University of Seville
name: RAQUEL GARCÍA DE LA PEÑA, DOCTOR
role: STUDY_DIRECTOR
References:
Clinical trial NCT04579913: A Multi-center, International Prospective Follow up Study
Official title: A Multi-center, International Prospective Follow up Study to Assess the Safety and Efficacy of the iTind Procedure After Three to Five Years of Follow Up
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Benign Prostatic Hyperplasia (BPH)
Lead sponsor: Medi-Tate Ltd.
Sponsor class: INDUSTRY
First posted: 2020-10-08
Enrollment: 17
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient who participated in the MT-03 study in the iTind arm who had not undergone an alternative procedure for BPH during the first 12 month follow-up period and who is willing to participate in the current follow up study.

Brief summary: The study objective is to assess the safety and efficacy of iTind three to five years following treatment.

Detailed description: This study will recruit patients who participated in the MT-03 study in the iTind arm to assess the safety and efficacy of the iTind procedure at three to five years following treatment as demonstrated by reduction of symptoms measured by IPSS and QoL and improvement of functional parameters as measured by peak urinary flow and PVR. Sexual and erectile function will also be assessed alongside the incidence of any related late occurring adverse events.

Eligibility criteria: Inclusion Criteria:

1. Subject signed informed consent form (ICF)
2. Subject who had participated in the MT-03 study in the iTind arm
3. Subject able to comply with the study protocol.

Exclusion Criteria:

1. Any anatomical or physiological condition that in the opinion of the investigator likely to impede successful completion of the study
2. Patients that are known to have had undergone an alternative surgical procedure for BPH during MT-03 study.

Primary outcomes:
measure: iTind Durability
timeFrame: 36 months post procedure
measure: iTind Durability
timeFrame: 48 months post procedure
measure: iTind Durability
timeFrame: 60 months post procedure
Secondary outcomes:
measure: iTind Efficacy
timeFrame: 36 months post procedure
measure: iTind Efficacy
timeFrame: 48 months post procedure
measure: iTind Efficacy
timeFrame: 60 months post procedure
measure: iTind Efficacy
timeFrame: 36 months post procedure
measure: iTind Efficacy
timeFrame: 48 months post procedure
measure: iTind Efficacy
timeFrame: 60 months post procedure
measure: iTind Safety
timeFrame: 36 months post procedure
measure: iTind Safety
timeFrame: 48 months post procedure
measure: iTind Safety
timeFrame: 60 months post procedure
Other outcomes:
Locations:
city: Pompano Beach
country: United States
facility: Clinical Research Center of Florida
state: Florida
city: Manhattan
country: United States
facility: Manhattan Medical research
state: New York
city: New York
country: United States
facility: Premier Urology Group
state: New York
city: New York
country: United States
facility: Lenox Hill Hospital
state: New York
city: Toronto
country: Canada
facility: Toronto
state: Ontario
Study officials:
References:
Clinical trial NCT05198713: Evaluation of Hearing Aid Benefit
Official title: Evaluation of Hearing Aid Benefit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss, Sensorineural
Lead sponsor: Sonova AG
Sponsor class: INDUSTRY
First posted: 2022-01-20
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The present study will investigate the benefit of hearing aids for speech intelligibility (in both quiet and noisy environments) compared to the unaided condition. Participants will include adults with moderate to moderately severe hearing impairment. The participants will complete laboratory-based speech intelligibility assessments with binaural hearing aids and without hearing aids.


Eligibility criteria: Inclusion Criteria:

* Moderate to moderately severe sensorineural hearing loss
* Willingness to wear custom hearing instruments during the study.
* Age-normal cognition
* Ability to attend on-site study visits.

Primary outcomes:
measure: Speech Intelligibility in Quiet.
timeFrame: Day 1 and Day 15
Secondary outcomes:
measure: Speech Intelligibility in Noise, Expressed as the Signal to Noise Ratio at Which Participant Can Correctly Repeat 50% of the Words
timeFrame: Day 1 and Day 15
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Phonak Audiology Research Center
state: Illinois
Study officials:
affiliation: Sonova AG
name: Kevin Seitz-Paquette, AuD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04717713: The Effect of Local Intraoperative Steroid Administration on Post-ACDF Dysphagia
Official title: The Effect of Local Intraoperative Steroid Administration on Post-ACDF Dysphagia - A Prospective Double-Blinded Study by High Resolution Impedance Manometry
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Swallowing Function
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-01-22
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Few methods were available to determine which muscle groups are associated with PD in details in previous investigations. Local steroid administration has shown some effects on PD in a large number meta-analysis. In this study, we aimed to conduct a prospective randomized-double blinded study to exam the efficacy and the safety of the local steroid administration on ACDF patients by using high resolution impedance manometry in patients receiving ACDF.

Detailed description: Postoperative dysphagia (PD) is the most common complication after anterior cervical discectomy and fusion (ACDF). However, few methods were available to determine which muscle groups are associated with PD in details in previous investigations. Local steroid administration has shown some effects on PD in a large number meta-analysis. In this study, we aimed to conduct a prospective randomized-double blinded study to exam the efficacy and the safety of the local steroid administration on ACDF patients, and the also apply the high resolution impedance manometry (HRIM) on patients receiving ACDF for better delineation of the swallowing function. Pressure-flow analysis (PFA), derives pharyngeal pressure flow variables obtained from HRIM were used to analyze the mechanisms of PD.

Eligibility criteria: Inclusion Criteria:

* patients undergoing elective anterior cervical spine surgery

Exclusion Criteria:

* patients receiving spine surgery not at the first time
* patients with head and neck cancer
* patients receiving other surgeries at head and neck region
* patients had previous swallowing difficulty history

Primary outcomes:
measure: pharyngeal pressure
timeFrame: preoperative, postoperative 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT01398813: X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey
Official title: Survey of X-Linked Hypohidrotic Ectodermal Dysplasia Carrier Women's Outlook Towards Reproduction, Potential XLHED Treatments and Genetic Testing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypohidrotic Ectodermal Dysplasia
X-Linked Hypohidrotic Ectodermal Dysplasia
Keywords: HED
XLHED
Lead sponsor: Edimer Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2011-07-21
Enrollment: 500
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will enroll XLHED carrier females

Brief summary: In this survey of X-Lined Hypohidrotic Ectodermal Dysplasia (XLHED) carrier females, Edimer proposes to review responses to an XLHED Carrier Outlook toward Reproduction Survey in order to understand attitudes toward reproduction, potential treatments and genetic testing in order to improve the understanding of the decisions that XLHED carrier females make regarding their reproductive future.

Detailed description: The full survey is available here: https://www.surveymonkey.com/s/X-CORS

For more questions or more details you may contact the Principal Investigator, Carrie Milliard: MILLIC@mmc.org or 207-662-6712

Eligibility criteria: Inclusion Criteria:

1. Provide signed informed consent;
2. 18 years of age or older
3. Females with:

   * the clinical characteristics of HED, including at least two of the following characteristics:

     * clinical signs and symptoms of HED:

       * a history of decreased sweating;
       * abnormal teeth (fewer permanent teeth, teeth are smaller than average and often have conical crowns);
       * sparseness of scalp and body hair;
   * AND

     * a clinical diagnosis from a healthcare professional;
     * or at least one HED affected family member
   * OR genetically confirmed HED or XLHED;

Primary outcomes:
measure: To study the outlook of XLHED carrier females toward reproduction, potential XLHED treatments and genetic testing.
timeFrame: study day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Carrie Milliard
state: Maine
Study officials:
affiliation: Maine Medical Partners Pediatric Specialty Care
name: Carrie Milliard, CGC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06542913: Left Lobe Versus Right Lobe in Adult Living Donor Liver Transplantation in Borderline GRWR
Official title: Left Lobe Versus Right Lobe in Adult Living Donor Liver Transplantation in Borderline GRWR: Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Liver Transplant; Complications
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-08-07
Enrollment: 30
Sex: ALL
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients presented to our center for LDLT

Brief summary: a prospective cohort study comparing outcomes of left lobe and right lobe adult living donor liver transplantation


Eligibility criteria: Inclusion Criteria:

* GRWR below 1

Exclusion Criteria:

* patients with renal impairment portal vein thrombosis vascular complications

Primary outcomes:
measure: small for size syndrome
timeFrame: 1 year
Secondary outcomes:
measure: other complications after LDLT
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02042313: Postoperative Pain Management After Minimally Invasive Esophagectomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Esophageal Cancer
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2014-01-22
Enrollment: 58
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Esophagectomy is a major surgical procedure often associated with significant morbidity and mortality and significant level of postoperative pain. In contrast to open esophagectomy where epidural pain control has been considered as a gold standard and could be crucial in affecting outcome the analgesic scheme for minimally invasive esophagectomy (MIE) is yet to be established. We would like to compare continuous epidural analgesia and continuous paravertebral block combined with single shot subcostal transversus abdominis plane (TAP) block in the analgesic effects, levels of cytokines, and postoperative complications in patients receiving MIE.


Eligibility criteria: Inclusion Criteria:

* Patient has a physical status between ASA I and III
* 20 - 75 years of age
* Patient has signed an informed consent
* Without contraindication of GA, EA or PVB

Exclusion Criteria:

* ASA \> III
* Inability to provide informed consent
* Bleeding disorders
* Being pregnant
* Contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs),
* Allergy to amide-type local anesthetics or NSAIDs
* Infection at the thoracic paravertebral injection site
* Severe spine or chest wall deformity
* Patients with major psychosis or drug and alcohol abuse
* Patients with a history of significant neurological, psychiatric, neuromuscular, cardiovascular, pulmonary, renal or hepatic disease
* Patients with physical disability that precludes complete cooperation

Primary outcomes:
measure: Intraoperative hypotension ( > 30% decline in the preoperative systolic/diastolic blood pressure)
timeFrame: during operation
Secondary outcomes:
measure: NRS pain score
timeFrame: postoperative day 0 to 4
Other outcomes:
measure: Tidal volume
timeFrame: postoperative day 1 to4
Locations:
city: Taipei
country: Taiwan
facility: Koo Foundation Sun Yat-Sen Cancer Center
Study officials:
References:
Clinical trial NCT04743713: Turkish Cross-cultural Adaptation, Validation and the Reliability of UWRI (University of Wisconsin Running Injury and Recovery Index)
Official title: Turkish Cross-cultural Adaptation, Validation and the Reliability of UWRI (University of Wisconsin Running Injury and Recovery Index)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Running Related Injuries
Keywords: validity
reliability
PRO
Patient Outcome Report
Turkish
Adaptation
Running
Injury
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2021-02-08
Enrollment: 90
Sex: ALL
Minimum age (years): 14
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Runners

Brief summary: The purpose is to perform a scientific study on TURKISH cross-cultural adaptation, validation and the reliability of UWRI

Detailed description: The primary aim of this study is to perform Turkish cross-cultural adaptation, validation and the reliability of UWRI in runners. The secondary aim of this study is investigating injury rate and types among runners.

Eligibility criteria: Inclusion Criteria:

* 14-45 years old female or male
* Participating in running as amateur, recreational, competitional or professional runner
* Being a short, mid, or long distance runner
* Being native Turkish speaker
* Agreed to participate in the research

Exclusion Criteria:

* If there is no surgical history related to running injury in the last 12 months
* If have chronic metabolic disease
* Paralympic athletes
* Pregnant and breastfeeding

Primary outcomes:
measure: Validity and reliability
timeFrame: 5-7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
state: Çankaya
Study officials:
References: